Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

	Mar '19	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
revenue	2.32M -	67.69M 2,812.61%	23.80M 64.85%	55.29M 132.34%	61.28M 10.84%	124.80M 103.65%
cost of revenue	606K -	1.13M 86.63%	2.06M 81.87%	8.97M 335.88%	13.13M 46.42%	15.56M 18.53%
gross profit	1.72M -	66.56M 3,774.16%	21.74M 67.34%	46.32M 113.08%	48.15M 3.96%	109.23M 126.85%
selling and marketing expenses
general and administrative expenses	237.21M -	335.77M 41.55%	259.88M 22.60%	775.03M 198.23%	600.51M 22.52%
selling general and administrative expenses	237.21M -	335.77M 41.55%	259.88M 22.60%	775.03M 198.23%	600.51M 22.52%	687.44M 14.48%
research and development expenses	512.99M -	263.22M 48.69%	236.63M 10.10%	483.04M 104.13%	525.22M 8.73%	501.74M 4.47%
other expenses			-33.41M -	-81K 99.76%	-62.19M 76,681.48%	-85.03M 36.72%
cost and expenses	750.81M -	600.11M 20.07%	498.56M 16.92%	1.27B 154.14%	1.14B 10.12%	1.20B 5.79%
operating expenses	750.21M -	598.98M 20.16%	496.50M 17.11%	1.26B 153.39%	1.13B 10.52%	1.19B 5.64%
interest expense	7.54M -	7.68M 1.95%	2.81M 63.44%	7.04M 150.66%	27.97M 297.22%	34.78M 24.35%
ebitda	138.13M -	83.85M 39.29%	-510.50M 708.79%	-1.50B 193.79%	-1.11B 26.15%	-996.51M 10.03%
operating income	-748.49M -	-532.42M 28.87%	-1.07B 101.14%	-1.21B 13.15%	-1.08B 11.07%	4.24B 493.67%
depreciation and amortization	748.49M -	532.42M 28.87%	560.39M 5.25%	-288.08M 151.41%	-30.01M 89.58%	22.04M 173.43%
total other income expenses net	-58.69M -	-28.56M 51.34%	172.35M 703.45%	288.00M 67.10%	-147.26M 151.13%	5.22B 3,645.80%
income before tax	-807.18M -	-560.99M 30.50%	-898.55M 60.17%	-923.75M 2.80%	-1.22B 32.59%	4.25B 447.27%
income tax expense	2.62M -	7.12M 171.49%	1.69M 76.33%	369K 78.11%	5.19M 1,306.50%	22.22M 328.21%
net income	-1.04B -	1.20B 215.22%	-900.23M 174.99%	-924.12M 2.65%	-1.23B 33.10%	4.35B 453.56%
weighted average shs out	215.35M -	215.35M 0%	684.79M 217.98%	669.75M 2.20%	712.79M 6.43%	783.25M 9.88%
weighted average shs out dil	215.35M -	215.35M 0%	684.79M 217.98%	669.75M 2.20%	712.79M 6.43%	831.05M 16.59%
eps	-4.84 -	5.57 215.08%	-1.31 123.52%	-1.38 5.34%	-1.73 25.36%	5.55 420.81%
epsdiluted	-4.84 -	5.57 215.08%	-1.31 123.52%	-1.38 5.34%	-1.73 25.36%	5.23 402.31%

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

11.82

22/11 21:00

Market Cap

8.31B

Beta: -

Volume Today

11.09M

Avg: -

Preview